The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer.
Hans-Joachim Lueck
No relevant relationships to disclose
Kristina Luebbe
Honoraria - Roche
Joachim Bischoff
No relevant relationships to disclose
Nicolai Maass
No relevant relationships to disclose
Gabriele Feisel
No relevant relationships to disclose
Oliver Tome
No relevant relationships to disclose
Wolfgang Janni
Consultant or Advisory Role - Novartis; Roche
Honoraria - Roche
Research Funding - Novartis; Roche
Mustafa Aydogdu
No relevant relationships to disclose
Tanja Neuhoeffer
No relevant relationships to disclose
Angelika Ober
No relevant relationships to disclose
Bahriye Aktas
No relevant relationships to disclose
Tjoung-Won Park-Simon
No relevant relationships to disclose
Claudia Schumacher
No relevant relationships to disclose
Heinz-Gert Hoeffkes
No relevant relationships to disclose
Thomas Illmer
No relevant relationships to disclose
Harald Wagner
No relevant relationships to disclose
Keyur Mehta
No relevant relationships to disclose
Valentina Nekljudova
No relevant relationships to disclose
Sibylle Loibl
No relevant relationships to disclose
Gunter Von Minckwitz
No relevant relationships to disclose